Bridge Medicines Enters Agreement with Weill Cornell Medicine to Develop a Novel Sphingosine 1-Phosphate (S1P) Receptor Modulator

NEW YORK, NEW YORK – March 11, 2019

Bridge Medicines announced today an agreement with Weill Cornell Medicine to develop a novel sphingosine 1-phosphate (S1P) receptor modulator.  This small molecule program originated in the laboratory of Timothy Hla, Ph.D. formerly of Weill Cornell Medicine, now Boston Children’s Hospital, and was successfully advanced by the Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI).